Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
21.29
-1.12 (-5.00%)
At close: Feb 21, 2025, 4:00 PM
21.01
-0.28 (-1.32%)
After-hours: Feb 21, 2025, 7:32 PM EST
Spyre Therapeutics Revenue
In the year 2023, Spyre Therapeutics had annual revenue of $886.00K, down -61.96%.
Revenue (ttm)
$886.00K
Revenue Growth
-61.96%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
30
Market Cap
1.25B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SYRE News
- 3 days ago - Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation - PRNewsWire
- 15 days ago - Spyre Therapeutics Announces Grants of Inducement Awards - PRNewsWire
- 5 weeks ago - Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts - PRNewsWire
- 2 months ago - Spyre Therapeutics Added to the Nasdaq Biotechnology Index - PRNewsWire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 2 months ago - Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Shareholders to Inquire about Securities Investigation - Accesswire
- 2 months ago - Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies - PRNewsWire